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Abstract Mutations of HBsAg especially within the ‘‘a’’
determinant could alter the antigenicity of the protein
causing failure of HBsAg neutralization and escaping from
the host’s immune system, resulting in active viral repli-
cation and liver disease. This project aimed to investigate
mutation in the S gene region of HBV infected patients in
Golestan Province-Iran. HBV-DNA extractions from
plasma and PCR of 100 patients were performed. Direct
sequencing and alignment of S gene were applied using
reference sequence from Gene Bank database. All isolates
were belonged to genotype D, subgenotype D1, subtype
ayw2. Overall 92 point mutations occurred. Of them, 40
(43.47%) were missense and 52 (56.52%) were silent.
Mutations were detected in 95 cases (95%). Five of 40
mutations (12.5%) occurred in ‘‘a’’ determinant and 13
(32.5%), 17 (42.5%), and 2 (5%) were seen in antigenic
epitope regions of B cell, CD4
? and CTL, respectively.
Frame shift mutations were seen in 22 cases (22%). 14% of
mutations occurred at Major Hydrophilic Region(MHR)
area which P120T/S and R122K/T substitutions were the
most frequent ones (4%). Mutation in G145R of the S gene
was observed in one case. A large number of MHR mutants
are in association with failure of HBsAg detection, vaccine,
and immunotherapy escape. This study showed ‘‘a’’
determinant S gene mutations in HBV infected people with
HBsAg positivity in Golestan Province-Iran. The rate of
mutation in our study was 95%. Collectively, the results of
this project exhibited that most of mutations were clustered
in CD4
? antigenic epitopes.
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Introduction
Hepatitis B (HBV) is one of the most common infectious
diseases, which may lead to chronic liver disease, cirrhosis,
and hepatocellular carcinoma [1]. HBV S gene has three open
reading frames (ORFs), including pre-S1, pre-S2, and S gene;
its product is the small HBsAg protein SHB [2]. Full length
genome analysis of HBV subclassified them into eight geno-
types, named A to H [3]. The subtypes of HBV were originally
defined by antibodies raised against the small HBsAg (SHBs)
antigenic determinants are called as ayw1, ayw2, ayw3, ayw4,
ayr, adw2, adw4, adrq- and adrq? serotypes. With the
emergence of complete HBV genome, eight genotypes from
A to H were identified based on more than 8% of differences
[4]. There is a certain correlation between serotype and
genotype, but it is far from perfect [3]. HBV replicates to high
titers in infected individuals, the replication of HBV DNA
proceeds through a RNA reverse transcriptase intermediary
step, since the reverse transcriptase activity of the HBV
polymerase protein lacks a proof-reading function, random
mis-incorporation of bases into the replicating DNA strand
A. Moradi  S. Zhand  A. Ghaemi  N. Javid 
A. Tabarraei (&)
Infectious Diseases Research Centre, Department
of Microbiology, School of Medicine, Golestan University
of Medical Sciences, Gorgan, Iran
e-mail: alijant@yahoo.com; tabarraei@goums.ac.ir
A. Moradi
e-mail: abmoradi@yahoo.com
S. Zhand
e-mail: sa_zh2006@yahoo.com
A. Ghaemi
e-mail: ghaem_amir@yahoo.com
N. Javid
e-mail: naeme_javid@gmail.com
123
Virus Genes (2012) 44:382–387
DOI 10.1007/s11262-012-0715-z
occurs [5]. Mutation in the HBsAg, have now been docu-
mented worldwide [6]. The HBsAg ‘‘a’’ determinant (amino
acids 124–147) is located within the major hydrophilic region
(MHR amino acids 99–169) of this surface protein [7]. The
potent B-cell epitope of HBsAg is borne by aa 124–147 of the
S gene product, making two loop structures maintained by a
disulfide bond between Cys-124 and Cys-137 as well as Cys-
139 and Cys-147 [4]. Subtyping and genotyping of HBV is
based on rasing of variety of antibodies against the ‘‘a’’
determinant [8]. Mutation of HBsAg particularly within the
‘‘a’’ determinant could alter the antigenicity of the protein,
leading to fail neutralization of HBsAg by anti-HBs antibody
and may cause escaping from the host’s immune system [2].
Amino acid substitutions within the ‘‘a’’ determinant of
HBsAg can lead to conformational alterations that may affect
the binding of neutralizing antibodies. The first described
escape mutation is G145R, which is related to a Guanine to
Adenine mutation at nucleotide position 587. Many other
substitutions described within the ‘‘a’’ determinant in the
HBsAg, were outside of ‘‘a’’ determinant sequence and in the
pre-S region [9]. A molecular model of HBV polymerase
indicated that substitution in residues that located beneath the
template strand of HBV nucleic acid near the active site of the
reverse transcriptase may enhance polymerization either by
repositioning the template strand of nucleic acid or by
affecting other residues involved in the polymerization reac-
tion [10]. Iran is considered as a country with low endemicity
of chronic HBV infection [11] however, comparing to higher
prevalence of HBV infection in Golestan Province with about
8.9% in comparison with other studies published in Iran to
date (3%) [12]. Recent study in our research group has showed
85% efficiency of HBV vaccination in children aged under
1 year old, that 85% of them were Anti-HBs positive and
Anti-HBc negative, and among 15% of them 4 were Anti-HBs
and Anti-HBc positive and one of them was HBsAg positi-
ve,were which is lower than universal predicted rate of 95%
[13]. This study aimed to investigate the rate of mutation in the
S gene region of HBV in patients infected by this virus in
Golestan Province-Iran.
Materials and methods
Sample selection
In this study, one hundred patients with proved HBV
infection by Real-time PCR who have been referred by
specialist for HBV infection diagnosis to virology diag-
nostic laboratory of Golestan University of Medical Sci-
ences were entered in this study. None of the patients were
vaccinated for HBV or had immunoglobulin therapy; all
patients were negative for antibodies against hepatitis C,
hepatitis D and human immunodeficiency virus. In addition
to these samples, HBV-DNA positive and HBV-DNA
negative control groups were also used. Blood samples
were collected in anti-coagulant EDTA 5% and plasma was
separated and used for further examination. All patients has
been tested for serological marker of HBV (HBsAg) using
commercial ELISA kit from DIALAB GmbH. All the
samples were HBsAg positive.
DNA extraction
HBV-DNA was extracted from 200 ll plasma for each
sample using QIAamp DNA Mini Kit (QIAGEN, Hamburg,
Germany) following the manufacturer’s instruction.
Extracted DNA was stored at -20C for PCR.
Primer selection
Suitable primers were selected to achieve maximum sen-
sitivity for PCR to amplify the S gene region providing
common regions for three types of surface antigens and
first loop of ‘‘a’’ determinant. Following primers were
yielded a 482 bp amplification product corresponding to
nucleotide position 250–732 [6].
F-50-CTA GAC TCG TGG TGG ACT TCT C-30.
R-50-AAG CCA NAC ART GGG GGA AAG C-30.
PCR and DNA amplification
5 ll of extracted DNA was added to an amplification
mixture containing 5 ll of 10X PCR buffer, 5 ll of MgCl2
(25 mmol/L), 0.5 ll of dNTP (10 Mm), 0.5 ll of Taq
DNA polymerase (QIAGEN, Hamburg, Germany) (5 U/ll)
and 1 ll of each primers (10 pmol) in a total volume of
50 ll with distilled water. The PCR profile was an initial
5 min denaturation at 94C, followed by 30 cycles of
amplification including denaturation for 20 s at 94C, pri-
mer annealing for 30 s at 60C and extension for 40 s at
72C, with a final extension at 72C for 5 min. The 482 bp
amplification products were analyzed by gel electrophore-
sis on 1.5% agarose gel stained with ethidium bromide to
determine HBV-DNA positive and negative samples.
DNA sequencing and mutation analysis
The positive PCR products were subjected for automated
sequencing (Metabion Company). For detection of muta-
tion and analysis, nucleotide sequences were aligned with
standard hepatitis B sequence [14, Accession number:
AB033559] from Gene Bank database, And also with
standard hepatitis B sequence of Iran in Gene Bank [8,
Accession number: GU938305].
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Results
The mean age of patients was 35.46 years. Of them 61%
were male and 39% were female. Comparison of our
nucleotide sequences with reference sequence showed all
isolates were belonged to genotype D based on previous
study [15], subgenotype D1, subtype ayw2, according to
information that summarized in Table 1 based on amino
acid residues specifying determinants of HBsAg [3]. Only
three cases showing A70P mutations were HBeAg positive.
In the case of Amino acid mutation level, our findings
with using Gene Runner software revealed the occurrence
of 92 point mutations with 40 mutations (43.47%) as
missense (amino acid altering) mutation and 52 mutations
(56.52%) as silent (no amino acid altering) mutation. Of
100 patients, 73 (73%) of them showed point mutations in
the region from nucleotide 143–582 that codes amino acids
47–194. Frame shift mutations were also showed in 22
patients (22%). Five of them (5%) did not show any
mutations in their S region.
Most of the frame shift mutation (68.18%) was hap-
pened at amino acid positions 150 and 152.
In the case of point mutation distribution and frequency
in the patients, our results were demonstrated 43 (58.90%)
with single mutation, 13 (17.80%) with double mutations, 7
(9.58%) with triple mutations, 7 (9.58%) with four muta-
tions, and 2 (2.72%) with five mutations in the sequenced
region of them (Table 2).
Data from amino acid mutation level were described
substitution of A70P in 58 (58%) cases and substitution of
A70T in 2 (2%) cases with no significant effect on immune
response. HBsAg MHR region possessed 14% of whole
mutations and the positions that amino acid changes
occurred are as following: Y100F, L109R, I110L, G112R,
S117I, P120S/T, R122K/T, M133I, Y134H, T140I, S143L,
G145R, G159R, E164V 0.5 of 40 mutations (12.5%) was
occurred in ‘‘a’’ determinant. Distribution of these
mutations was at M133I, Y134H in the first loop of ‘‘a’’
determinant and the rest of substitutions including T140I,
S143L and G145R were occurred in the second loop of ‘‘a’’
determinant.
MHR variants with known functional effects are shown
in Table 3. The variants involved in failure of HBsAg
detection were found in samples of 11 patients (11%). The
variants involved in immunotherapy escape were detected
in samples of 5 patients (5%) whereas variants associated
with vaccine escape were detected in samples of 4 patients
(4%). The amino acid substitution G145R, which is asso-
ciated with vaccine escape, was identified in one isolate
(1%).
According to the proposed residues of antigenic epitopes
within the HBV surface protein, our results demonstrated
that of 40 amino acid changes, 13 (32.5%), 17 (42.5%),
2(5%) were seen in B cell epitopes, CD4
? and CTL
Table 1 HBsAg amino acid determinants and distribution of HBV
genotypes and subtypes [18]
Position Amino
acid
Specify Genomic
group
Subtype Areas of high
prevalence
122 Lys d
Arg y
127 Pro w1
a/w2 D ayw2 Mediterranean
area
Thr w3
160 Leu/
Ileu
w4 ayw3 India
Lys w
Arg r
a w1 reactivity also requires Arg 122, Phe 134, and/or Ala 159
Table 2 Distribution of frequency and position of point mutations in
HBV patients in Golestan Province-Iran
No (%) Frequency of
point mutation
Position
43 (58.90) 1 A70P, G71X, R122T/K, L87M,
P120S, I82L
13 (17.80) 2 A70P, V177L, P62L, L87M, M133I,
L175F, I82L, P120S, S55C, A70T,
S143L, T140I , Y134F, G145R,
R79H
7 (9.58) 3 A70P, P62A, C65S, L186R, T189L,
E164V, V190L, P62L, S64F, T140I
7 (9.58) 4 R79F, F80L, F85C, L89P, I110L,
P120T, V190L, L89I, L109R,
S117I, R122T, Y100F, L109R
2 (2.72) 5 G112R, P120S, R122T, W74G,
M75R, L77M, A70T, S193 N,
V194Y, P62L
Total 73 (100%)
Table 3 Amino acid substitutions in the MHR of HBsAg with known
functional effects according to Avellon and Echevarria [26]
Substitution
in MHR
Number
of cases
Description
Vaccine
escape
Immunotherapy
escape
Failure of
HBsAg
detection
P120S n = 3 ? - ?
P120T n = 1 - ? ?
R122K n = 4 - - ?
M133I n = 1 - ? ?
T140I n = 2 - ? -
S143L n = 1 - - ?
G145R n = 1 ? ? ?
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epitopes, respectively and 8 mutations (20%) were out of
these regions (Table 4).
Discussion
We have aligned our identified hepatitis B surface protein
genotype and subtype with gene bank standard [14,
Accession number: AB033559] and Iranian introduced
strain [8, Accession number: GU938305]. All isolates were
belonged to genotype D, subgenotype D1 and subtype
ayw2; these are comparable with other cases studied in Iran
by Daram et al. [16] Norouzi et al. [8], and Hamkar et al.
[17]. Our previous study as well shown that all isolates of
HBV in Golestan Province were belonged to genotype D
[15]. This was in accordance with other studies reporting
subgenotype D1 and subtype ayw2 are prevalent in Medi-
terranean area [3].
In comparison with previous reports from different part
of Iran, showing 100% mutations in S gene region of iso-
lated HBV [8, 16, 17], our findings showed some cases
(5%) of HBV without any mutation in their S region. We
have demonstrated mutations in 95% of patients showing
lower rate of mutation than reports from Iran.
The most common mutation in this study was occurred
at position A70P in 58 (58%) patients. However, it is not
located in the antigenic epitopes within the HBV surface
protein; compared to results in Daram et al. [16] and
Norouzi et al. [8] studies. Also we have not seen this
mutation (A70P) in 13 (13%) cases. For the first time, we
also have find amino acid substitution at position A70T in 2
(2%) patients.
Mutations especially at ‘‘a’’ determinant region are able
to impair the binding of neutralizing antibodies to the viral
surface; viruses carrying such mutated T-cell epitopes
cannot be recognized by specific T-cells of an individual,
hence, will not enhance anti-HBs production, this could be
led to the progression of chronicity of HBV infection. The
importance of such mutations in different antigenic epi-
topes within HBV proteins in the pathogenesis of chronic
HBV is a matter of debates. Some authors believe that CTL
epitopes have a major role; a majority of chronic HBV
carriers contained mutated residues within CTL epitopes.
Others, however, showed that these mutations occurred in
the CD4
?/B cell epitopes [16].
Our study showed that, most of the amino acid substi-
tutions (32 of 40 amino acid changes) 80% occurred in
different antigenic epitopes of S gene, with distribution of
13 (32.5%) in B cell epitopes, that 5 of them were located
in ‘‘a’’ determinant, 17 (42.5%) in CD4
? and 2(5%) in CTL
epitope, whereas 8 mutations (20%) were positioned out of
this region. It is comparable with data reported by Norouzi
et al. [8] describing occurrence of 42.1% mutations in
CD4
? epitope. But is different from findings of Daram
et al. [16] in Iran showing most occurrence of mutations in
CTL epitope (27.2%).
According to the study on Moroccan HBV infected
patients, the global prevalence of MHR variants was 15%
with the most frequent substitution at position P120T/S
(3.7%) [18]. In Serbia mutation in MHR of HBV patients has
been reported by overall frequency of 22.6% and substitution
at position 120 (9.1%) was the most frequent [19]. This
frequency has been reported in Argentina with 14.8% MHR
mutation [20]. These are comparable with our results
showing overall frequency of 14% MHR mutations with the
most frequent ones of P120T/S and R122K/T (4%).
Interestingly, in comparison with a study of 249 sera
from HBV-infected patients living in 25 Provinces of
Iran [8], which were reported most frequent mutations of
isolates was located at positions S143L, I10L, G101A,
T118A, S136T, T118L, and P120S, our findings showed
different feature of mutations with just two similar muta-
tion at positions S143L and P120S/T. This difference could
be due to high variability of sampling from different area of
Iran that showing different pattern of above mutations in
different Provinces.
Table 4 Distribution and
position of S region mutations
in proposed antigenic epitopes
[8]
Patients sequence Cell subsets Amino acid Reference
Y100F, L109R, I110L, G112R, S117I, P120S/T, R122K/T,
M133I, Y134H/F, T140I, S143L, G145R, G159R
B cell 100–160 Honirati
– Th (CD4) 19–28 (Ducos 1996)
P62L, C65S, S55C, S64F Th (CD4) 21–65 (Mancini 2006)
F80L, I82L, F83C, F85C, L87M, L89I Th (CD4) 80–98 (Ducos 1996)
L186R, T189L, V190G, W191A, L192Y, S193N, V194Y Th (CD4) 186–197 (Mancini 2006)
– Th (CD4) 215–223 (Ducos 1996)
L175F, V177L CTL (CD8) 171–179 (Barnab 1994)
– CTL (CD8) 175–184 Mancini-2006
– CTL (CD8) 206–215 Mancini-2006
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Substitutions in numerous residues of S gene including
positions 116, 118, and 120 could alter the ‘‘a’’ determinant
conformation [21]. Substations that lead to conformational
change of the ‘a’ determinant may cause a considerable
decrease of properly folded surface antigen, which may
render the virus particles less immunogenic in inducing an
effective neutralizing antibody to clear the virus [6].
Nucleotide substitutions that lead to amino acid changes
within the second loop of ‘‘a’’ determinant may result in
reduced binding or failure to detect serum HBsAg in
diagnostic assays with polyclonal and/or monoclonal anti-
bodies [7]. However, some recent studies suggested that the
‘‘a’’ determinant region mutations did not play a major role
in HBsAg laboratory detection and paraclincal diagnosis of
occult HBV infection [8]. This is comparable with our
results that reveal all 100 patients were HBsAg positive by
DIALAB GmbH and shows following distribution in the
first and second loop of ‘‘a’’ determinant. M133I and
Y134H were occurred in the first loop of ‘‘a’’ determinant
and the rest of substitutions including T140I, S143L, and
G145R were occurred in the second loop of ‘‘a’’ determi-
nant. It may result in an increased likelihood of HBV
escaping identification by the immune system [6]. Our
findings showed most of mutations were happened in the
second loop of ‘‘a’’ determinant and is different with results
of a study in Turkey that reveals higher rate of mutations at
the first loop of ‘‘a’’ determinant [6].
In addition, De Maddalena et al. [22] found that geno-
type D strains carry more mutations in the ‘‘a’’ determinant
of HBsAg with potential escape mutants in non-vaccinated
subjects. Therefore, they indicate the need for careful
surveillance of these variants in areas in which genotype D
predominates.
The first description of an HBsAg escape mutant was
made in a child born to an HBsAg-positive mother who
developed acute hepatitis B despite being vaccinated and
passively immunized against HBV [23]. The variant
G145R seems to be the hottest spot for an escape mutation
to occur and usually selected under immune pressures after
administration of the HBV vaccine with or without con-
current HBIg, or following treatment with polyclonal or
monoclonal HBIg, and caused to reduce affinity of HBsAg
to antibodies induced with vaccination [24]. Naturally
occurring surface gene variants have also been reported
around the world in persons who have not been immunized
[7]. Identified viral mutants are naturally circulating,
because none of these patients were vaccinated with HBV
or had immunoglobulin therapy. Escape mutants with
mutations in the S gene would pose a substantial risk to the
community, because current hepatitis B immunoglobulin
and vaccines are not effective in preventing infection with
them [25]. This substitution reported as a vaccine-escape
mutation [4]. In our study, we found one patient (1%) that
displayed G145R substitution for the first time in Iran [8,
16, 17]. This frequency was similar to results reported in
Spain and Serbia, 1.5 and 1.8%, respectively [19, 26].
Therefore, the presence of immune-escape mutants in our
population should be considered in the immunization pro-
gram (Fig. 1).
According to the study on Moroccan HBV infected
patients, the global prevalence of MHR variants was 15%
with the most frequent substitution at position P120T/S
(3.7%) [27]. In Serbia mutation in MHR of HBV patients
has been reported by overall frequency of 22.6% and
substitution at position 120 (9.1%) was the most frequent
[19]. This frequency has been reported in Argentina with
14.8% MHR mutation [20]. These are comparable with our
results showing overall frequency of 14% MHR mutations
with the most frequent ones of P120T/S and R122 K/T
(4%).
The clinical characteristics of patients with MHR vari-
ants indicate a significant association between the occur-
rence of MHR variants and advancing age of the patients
([40 years). This result was consistent with that obtained
by study in morocco [27] and could be explained that older
age is more associated with longer history of HBV
infection.
It has been demonstrated that the M133 V substitution
led to the antigenic alteration [18]. Mutation at amino acid
position M133I were already reported by Oon et al. [28],
who has been shown that this mutation increase ability of
vertical transmission of HBV to fetus. Further study in the
case of babies who were born from HBV infected mothers
should be done to confirm above idea. In our study, M133I
substitution was found in 1(1%) case, and this case was
female that indicates more consideration should be done
about this group of patients to avoid prevalence of disease
in the whole society.
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Fig. 1 Frequency and distribution of amino acid substitutions in the
MHR of HBsAg in 19 patients
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Conclusion
A large number of MHR mutants are in association with
failure of HBsAg detection, vaccine, and immunotherapy
escape. This study showed S gene ‘‘a’’ determinant muta-
tion in HBV infected people in Golestan Province-Iran.
Our results demonstrate that the rate of mutations in S gene
residues was 95%, while 5% of our samples were without
any mutations. Mutation in 145th amino acid of S gene in
genotype D of HBV is reported for the first time in Iran.
Mutations in second loop of ‘‘a’’ determinant may result in
an increased likelihood of HBV escaping identification by
the immune system. Collectively, the results of this project
exhibited that most of the mutations were clustered in
CD4
? antigenic epitopes.
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